The changing trajectory of diabetic kidney disease.

Purpose Of Review: Progression of diabetic kidney disease has slowed over the past 40 years by as much as 70-75%, thanks to a diversity of drug classes that have less effect on glucose and more on reducing cardiorenal risk.

Recent Findings: With the advent of sodium-glucose co-transporter 2 (SGLT2) inhibitors and the novel nonsteroidal mineralocorticoid antagonist, finerenone, we now have three 'pillars of therapy' considering the renin-angiotensin system (RAS) inhibitors as already established treatment to slow diabetic kidney disease. Both renal and cardiovascular outcomes trials have provided solid evidence of the benefit by these agents to slow kidney disease progression and reduce heart failure hospitalizations.

Artificial Intelligence in Acute Kidney Injury: From Static to Dynamic Models.

Artificial intelligence (AI) is the development of computer systems that normally require human intelligence. In the field of acute kidney injury (AKI) AI has led to an evolution of risk prediction models. In the past, static prediction models were developed using baseline (eg, preoperative) data to evaluate AKI risk.